SEC Form 4 · accession 0001209191-17-008661
Foundation Medicine, Inc. · FMI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven J. Kafka
Officer — President & COO
Period of report
Feb 6, 2017
Accepted (ET)
Feb 8, 2017 · 4:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001488613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 6, 2017 | A | 52,855 | $18.92 | A | 146,015 | D | |
| Common StockF2,F3 | Feb 8, 2017 | S | 10,415 | $23.24 | D | 135,600 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents restricted stock units granted by the Issuer pursuant to its 2013 Stock Option and Incentive Plan. These restricted stock units will vest in their entirety on 2/6/2018.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2016.
- F3The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.00 to $23.625, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.